Prevention of Clostridium Difficile Infection in High Risk Patients
The present invention relates to methods of preventing Clostridium difficile infection (COI) in a human subject who is at high risk of developing this infection, comprising administering to the subject an effective amount of the compounds described herein. In some embodiments, the subject is further receiving concomitant antibiotic therapy to prevent and/or treat an infection other than Clostridium . In some embodiments, the subject previously was treated for a Clostridium infection. In some embodiments, the compound of formula I prevents the Clostridium infection.
1 . A method of preventing a Clostridium infection in a human subject receiving treatment in an intensive care setting and who is at high risk of developing a Clostridium infection, comprising orally administering to the human subject an amount of a compound of Formula I:
effective to inhibit the proliferation of Clostridium in the gastrointestinal tract of the human subject.
2 . The method of claim 1 wherein the subject is a hematopoietic stem cell transplant (HSCT) patient.
3 . (canceled)
4 . The method of claim 2 wherein the subject is also suffering from Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML).
5 . The method of claim 1 wherein the Clostridium infection is caused by C. difficile.
6 . The method of claim 1 wherein the subject is further receiving concomitant antibiotic therapy to prevent and/or treat an infection other than Clostridium.
7 . The method of claim 1 wherein the subject previously was treated for a Clostridium infection.
8 . The method of claim 1 wherein the human subject has only received radiation therapy.
9 . The method of claim 1 wherein the human subject has only received chemotherapy.
10 . The method of claim 1 wherein the compound of Formula I is administered as a pharmaceutical composition.
11 . The method of claim 10 wherein the pharmaceutical composition further comprises butylated hydroxy toluene.
12 . The method of claim 10 wherein the pharmaceutical composition is administered orally.
13 . The method of claim 12 wherein the pharmaceutical composition is to a patient in a dosage range from about 50 mg to about 400 mg per day for 10 to 50 days.
14 . The method of claim 13 wherein the pharmaceutical composition is administered to a patient once a day at a dose of about 200 mg for 40 days.
15 . The method of claim 10 wherein the pharmaceutical composition contains at least 93% of the compound of Formula I.
16 . The method of claim 1 wherein the compound of Formula I is present as a crystalline polymorph with an X-ray diffraction pattern with peaks at diffraction angles 2θ 7.7°, 15.0° and 18.8°±0.2° as set forth in FIG. 1 .
17 . The method of claim 16 wherein the X-ray diffraction pattern is as set forth in FIG. 1 .